Therapeutic Antibodies – Multimedia

Binding affinity is a significant factor to consider. However, relying solely on affinity can be problematic, as the highest affinity mAbs may not exhibit optimal activity. To ensure the best lead candidates, it is crucial to consider factors like specificity, selectivity and biological relevance.

Download this infographic to explore why it is important to analyze biopharmaceuticals and some of the methods commonly used.

This whitepaper highlights the key molecular components of ADCs and the challenges and opportunities for their future development.

The development of antibodies for diagnostics or therapeutics requires comprehensive characterization of affinity, specificity and mechanism of action. In particular, antibody-drug conjugates (ADCs) are an exciting and emerging class of biopharmaceuticals with applications in cancer.

Biolayer Interferometry (BLI) technology has greatly advanced the process of antibody discovery, and the latest platforms offer reliable, high precision analysis which researchers can rely on.

For a smooth molecule journey from benchtop to clinic you need to make the most informed candidate selection and reduce the risk of failure and complications during development. Our BiacoreTM systems support informed decision-making during the lead candidate selection process. Its technology delivers valuable insights into developability such as manufacturability and safety.

According to the World Health Organization (WHO), cancer is a leading cause of death worldwide. Furthermore, recent estimates predict that as many as one in two people could develop a form of cancer in their lifetime.

In this episode of Opinionated Science we dive into the world of therapeutic antibodies with Bio-Rad.

Antibody drug conjugates (ADCs) are biotherapeutics, composed of small molecule drugs conjugated to an antibody scaffold, that have very complex molecular structures.

This is especially critical for bispecific antibodies, which are regarded as the second generation of antibody cancer therapies.